

References

S-207

1. National Comprehensive Cancer Network. Multiple Myeloma. Clinical practice guidelines in oncology, v.1. 2019.
2. Majhail N, Farnia S, Carpenter P, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015 ;(21):1863-1869.
3. Shah N, Callander N, Ganguly S, et al. Hematopoietic stem cell transplantation for multiple myeloma: Guidelines from the American Society for Blood and Marrow Transplantation (ASBMT). *Biol Blood Marrow Transplant*. 2015 ;(21):155-1166.
4. InterQual® Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
5. Garderet L, Cook G, Auner HW, et al. Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. *Leuk Lymphoma*. 2017; 58(4):797-808.
6. Autore F, Innocenti I, Luigetti M, et al. Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome. *Hematol Oncol*. 15 2017.
7. Cook G, Iacobelli S, van Biezen A, et al. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. *Haematologica*. 2017; 102(1):160-167.
8. Shah N, Callander N, Ganguly S, et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015; 21(7):1155-1166.
9. Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. *Biol Blood Marrow Transplant*. 2015; 21(12):2039-2051.
10. Qiao SK, Guo XN, Ren JH, et al. Efficacy and safety of lenalidomide in the treatment of multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. *Chin Med J (Engl)*. 2015; 128(9):1215-1222.

11. Maffini E, Storer BE, Sandmaier BM, et al. Long term follow-up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. *Haematologica*. 2018.
12. Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. *Lancet Haematol*. 2016; 3(7):e340-351.
13. Ziogas DC, Terpos E, Dimopoulos MA. When to recommend a second autograft in patients with relapsed myeloma? *Leuk Lymphoma*. 2017; 58(4):781-787.
14. McCarthy PL, Holstein SA. Role of stem cell transplant and maintenance therapy in plasma cell disorders. *Hematology Am Soc Hematol Educ Program*. 2016; 2016(1):504-511.
15. Schneidawind C, Duerr-Stoerzer S, Faul C, et al. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation. *Clin Transplant*. 2017; 31(7).
16. Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomized, multicenter, phase 3 trial. *Lancet Oncol*. 2015;16(16):1617-1629.
17. Marini C, Maia T, Bergantim R, et al. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. *Ann Hematol*. 2019;98(2):369-379.
18. Garderet L, Cook G, Auner HW, et al. Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. *Leuk Lymphoma*. 2017;58(4):797-808.
19. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 1.2021.